Abstract
New oral anticoagulants (NOACs) including dabigatran and rivaroxaban are approved for prevention of stroke in patients with atrial fibrillation (AF) [1]. To date, existing NOAC treatment is considered a contraindication for intravenous thrombolysis (IVT) in the case of acute stroke [2]. Nevertheless, rational approaches for the use of IVT in patients taking dabigatran have been published [3]. IVT under dabigatran treatment has been reported [4–6] but no data are available on rivaroxaban. Based on theoretical considerations, recent recommendations suggest that IVT might be considered in the case of low plasma levels of rivaroxaban [7]. We report on such cases. Case A
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
